Skip to main content

Table 1 Baseline characteristics of all patients in the follow up cohort

From: Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Number of patients 147
Age, years (mean, sd*) 58 (12)
Female, No (%) 101 (69)
Weight, kg (mean, sd) 73 (14)
Disease duration, years (mean, sd) 11 (7)
RF positive, No (%) 117 (81)
Anti-CCP positive, No (%) 95 (69)
DAS28 at inclusion (mean, sd) 3.5 (1.3)
Interval duration at inclusion, weeks (median, IQR) 8[48]
Previous DMARDs, weeks (median, IQR**) 3[2, 3]
Concomitant DMARD use, No (%) 111 (78)
Concomitant MTX use, No (%) 95 (67)
Previous anti-TNF-alpha therapy, No (%) 16 (11)
Duration of infliximab therapy, years (mean, sd) 2.5 (2.0)
  1. * sd = standard deviation.
  2. ** IQR= interquartile range.
\